TY - JOUR
T1 - Use of a Pseudomonas aeruginosa vaccine in patients with acute leukemia and cystic fibrosis
AU - Pennington, James E.
AU - Reynolds, Herbert Y.
AU - Wood, Robert E.
AU - Robinson, Richard A.
AU - Levine, Arthur S.
N1 - Funding Information:
From the Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases: Pediatric Metabolism Branch, National lnstltute of Arthritis, Metabolism and Digestive Diseases; and the Section on Infectious Disease, Pediatric Oncology Branch, National Cancer Instttute, National Institutes of Health, Bethesda, Maryland. Requests for reprints should be addressed to Dr. Herbert Y. Reynolds, Bldg. 10, Rm. 118-13, National Institutes of Health, Bethesda, Maryland 20014. Manuscript accepted June 7, 1974. l Present address: Peter Bent Brigham Hospital, 721 Huntington Avenue, Boston, Massachusetts 02115. + Present address: Department of Pediatrics, Ralnbow Babies and Children’s Hospital, Case Western Reserve, 2103 Adelbert Road, Cleveland, Ohio 44106.
PY - 1975/5
Y1 - 1975/5
N2 - A heptavalent lipopolysaccharide Pseudomonas vaccine was evaluated in 22 patients with acute leukemia and 12 patients with cystic fibrosis during an 18 month interval at the Clinical Center of the National Institutes of Health. Of the 34 patients, 32 had an excellent serum hemagglutinating (HA) antibody response to immunization. In comparison to the patients with cystic fibrosis, the patients with leukemia had a smaller HA antibody response, which lasted a shorter period of time, and also experienced greater toxicity from the vaccine. The mixing of adrenal corticosteroids with vaccine greatly decreased side reactions among the patients with leukemia without significantly inhibiting antibody production. Previous antineoplastic chemotherapy had little influence on antibody response in patients with leukemia, with the exception of methotrexate. Vaccinated patients with leukemia had 1 Pseudomonas infection of 14 bacterial or fungal infections, whereas 2 Pseudomonas infections of 5 bacterial or fungal infections occurred in a control group of 20 patients with acute leukemia. Of the 12 patients with cystic fibrosis, 4 had a Pseudomonas infection after vaccination.
AB - A heptavalent lipopolysaccharide Pseudomonas vaccine was evaluated in 22 patients with acute leukemia and 12 patients with cystic fibrosis during an 18 month interval at the Clinical Center of the National Institutes of Health. Of the 34 patients, 32 had an excellent serum hemagglutinating (HA) antibody response to immunization. In comparison to the patients with cystic fibrosis, the patients with leukemia had a smaller HA antibody response, which lasted a shorter period of time, and also experienced greater toxicity from the vaccine. The mixing of adrenal corticosteroids with vaccine greatly decreased side reactions among the patients with leukemia without significantly inhibiting antibody production. Previous antineoplastic chemotherapy had little influence on antibody response in patients with leukemia, with the exception of methotrexate. Vaccinated patients with leukemia had 1 Pseudomonas infection of 14 bacterial or fungal infections, whereas 2 Pseudomonas infections of 5 bacterial or fungal infections occurred in a control group of 20 patients with acute leukemia. Of the 12 patients with cystic fibrosis, 4 had a Pseudomonas infection after vaccination.
UR - http://www.scopus.com/inward/record.url?scp=0016772036&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0016772036&partnerID=8YFLogxK
U2 - 10.1016/0002-9343(75)90498-2
DO - 10.1016/0002-9343(75)90498-2
M3 - Article
C2 - 805535
AN - SCOPUS:0016772036
SN - 0002-9343
VL - 58
SP - 629
EP - 636
JO - The American journal of medicine
JF - The American journal of medicine
IS - 5
ER -
